The CommonHealth

In the tenth episode of the CommonHealth Live! series, Katherine E. Bliss will sit down with Stacy Aguilera-Peterson, Deputy Director for Research, U.S. Global Climate Change Research Program, White House Office of Science and Technology Policy, and Josh Glasser, Assistant Director for Combatting Antimicrobial Resistance & Integrated Health Innovation (One Health), White House Office of Science and Technology Policy. The discussion will focus on how the Biden administration has sought to define the relationship between climate change and health, the extent to which climate-related impacts on health can be seen as threats to national security, and opportunities for stakeholders in research, program implementation, service delivery, and the private sector to collaborate with U.S. government agencies and international partners on addressing global challenges at the intersection of climate change and health. This event is made possible by the generous support of the Wellcome Trust and GSK.​​​

In the ninth episode of the CommonHealth Live! series, J. Stephen Morrison will sit down with Rahul Gupta, Director of the White House Office of National Drug Control Policy. Dr. Gupta will discuss the surprising 15 percent decline in overdose deaths in 2024, 70 percent of which are caused by fentanyl overdose, and what factors are driving this change. He will discuss measures taken nationally on treatment access and internationally on interdiction and related measures to reduce the flow of fentanyl. What more needs to be done to sustain progress and save more American lives? 

Dan Diamond, the national health reporter at the Washington Post, reflects on the shock of both United Health executive Brian Thompson’s tragic murder and the subsequent tsunami of anger and glee on social media. We’ve entered “a staggering moment” that does not feel real, but nonetheless reveals the remarkable depth of discontent with the American health system, in particular insurers. “Everything feels grey to me.” This moment is grounded in the collapse of trust, including trust in the media. United Health, America’s fourth largest firm, and the most powerful firm in the health sector, inevitably attracts—and will continue to attract—tough scrutiny and enduring questions over why the U.S. health system is so dysfunctional. This week Robert F. Kennedy, Jr. ventures to the Senate, where many Senate members simply do not know what to make of him. He has issued so many different statements on so many topics at different times to different audiences. While RFK Jr.’s vaccine positions will get the greatest play and are likely to remain a red line for Democrats, his pivot to chronic disease prevention and healthy food has rallied many to his side. Perhaps DOGE will be a vehicle for introducing progressive and budget reform ideas into the Republican Party in a new way. Will there be progress in changing the seasonal clock in America, a lighter, perennial topic? Probably not. There “is not a real path forward.”

Sheryl Gay Stolberg, the NYT health correspondent, feels her decades of health and political reporting prepare her well for understanding this remarkable moment in American history. Anger and alienation against the health sector and science are surging, drawing both on historical roots and current dynamics. Robert F. Kennedy, Jr. nominated to be HHS Secretary, taps into a profound mistrust that he has indeed stoked, aided by the platform Covid gave him to mobilize “vaccine resisters.” RFK Jr’s nomination has several advantages, including his pivot to prevention, the root causes of chronic diseases, processed foods, and declining life expectancy. He has moved past the extremes (heroin addiction, sexual patterns, conspiracies) to claim redemption and resilience. He appeals to populist dissatisfaction with “regulatory capture” by big pharma and big food. Opposition can be loud. Mike Bloomberg has declared RFK Jr. “beyond dangerous, “medical malpractice on a mass scale.” Scott Gottlieb, AEI, has issued similarly scathing statements. Opposition can be muted. While there is “terror” among industry, public health, academic centers, opponents are cautious, out of fear of retaliation.Jay Bhattacharya, Stanford, nominated to lead NIH, and others critics of the Biden administration feel they were marginalized during Covid and treated unfairly. “I think it is important that we engage with people on their ideas.” 

How do we explain the peril that global health faces? Covid and the post-Covid backlash. The Biden years’ “status quo” approach. Less support in Europe. Excessive debt in Africa. The generational shift in Congress and aging of the flagship programs: “Time has passed.” “We never really dealt with PEPFAR’s treatment mortgage.” Dealing with the conservative critique of US global health funding Is essential to revitalize bipartisanship. 2025 could be rocky, should resources shrink. “We need to be creative, and realistic.” What should we make of the emerging Trump leadership team, most significantly, Senator Rubio, Elise Stefanik, RFK Jr., and Jay Bhattacharya?

In the seventh episode of the CommonHealth Live! series, Katherine E. Bliss will sit down with Dr. John Balbus, Director of the Office of Climate Change and Health Equity at the U.S. Department of Health and Human Services. Dr. Balbus will speak about the foundation of his office in 2021, the work it has engaged in so far, lessons learned, and his vision for the future. This event is made possible by the generous support of the Wellcome Trust and GSK​​​

In the sixth episode of the CommonHealth Live! series, Katherine E. Bliss will sit down with Dr. Hanan Balkhy, WHO Regional Director for the Eastern Mediterranean. Dr. Balkhy will speak to her evolving vision for the region, encompassing EMRO’s multiple complex humanitarian operations—in Gaza, Yemen, Afghanistan, Libya, and beyond. She will also reflect on the growing challenge of antimicrobial resistance and what may come out of the UN High-Level Meeting on Antimicrobial Resistance (AMR) to be held on the margins of the UN General Assembly on September 26.This event is made possible through the generous support of the Bill & Melinda Gates Foundation. 

Javier Guzman, Center for Global Development debriefs on the High Level Meeting on Anti-Microbial Resistance held in New York City on September 26. Successes took several forms: significant new data, analyses, and projections; a political declaration committed to the creation of a scientific panel; elevation of equity of access and accountability; a target to reduce deaths by 10% by 2030; and agreement to convene again in 5 years. The panel has to be seen as a joint enterprise between the north and south. Emerging economies are getting more engaged. There are serious reservations among many countries that are heavily dependent on animal production. We do not have much visibility into what is happening in China. Data remains elusive. The $100m target of national governments commitment is “a drop in the ocean.” There is an urgent need for creative, large-scale financing and plans to bring to scale access to AMR technology. Countries themselves have to take control and commit. 

Dr. Michael Osterholm unpacks the history of H5N1, as we struggle with the question of whether the current H5N1 outbreak may pose a grave threat of a human-to-human pandemic. "It’s possible that H5N1 may never get over the bar for human disease and we don’t know why.” He also speaks to what we are likely to face in the months ahead from the mpox clade 1b outbreak, centered in Africa. 

Nidhi Bouri, DAA at USAID Bureau for Global Health, joined us to speak to the U.S. response to the dangerous mpox outbreak (clade 1b) centered in the Democratic Republic of Congo, boosted by President Biden’s commitment at UNGA to $500m in support, including 1 million vaccine doses. Much better data is urgently needed on the needs for diagnostics and vaccines. Tensions remain high among Africa CDC, WHO, and other key institutions with proven response capability, most notably Gavi, UNICEF and the Global Fund. Much is not known about modes of transmission, and the durability and efficacy of the Jynneos vaccine for clade 1b. As the virus inevitably lands in the United States, communications will be critical. Some important progress was seen in the High Level Meeting on anti-microbial resistance. The Marburg outbreak in Rwanda is of acute concern for multiple reasons: no vaccine, little testing, little knowledge of the pattern of spread. It is crunch time, as multiple replenishments converge. “Let’s be clear, there is not enough money.”